Table 3.
Overview of treatment and tumor characteristics for the salvage transoral robotic surgery group (N = 30).
| Characteristic | Value (N = 30) | % |
|---|---|---|
| Reason for salvage surgery | ||
| Local recurrence | 10 | 33.3 |
| Second primary tumor | 20 | 66.7 |
| Subsite | ||
| Oropharynx | 17 | 56.7 |
| Base of tongue | 8 | |
| Tonsil | 2 | |
| Posterior wall | 3 | |
| Vallecula | 2 | |
| Soft palate | 2 | |
| Supraglottic larynx | 6 | 20.0 |
| Epiglottis | 5 | |
| Aryepiglottic fold | 1 | |
| Hypopharynx (pyriform sinus) | 6 | 20.0 |
| Glottic larynx | 1 | 3.3 |
| Clinical tumor classification | ||
| cT1/rT1 | 18 | 60.0 |
| Oropharynx | 8 | |
| Supraglottic larynx | 4 | |
| Hypopharynx | 6 | |
| cT2/rT2 | 12 | 40.0 |
| Oropharynx | 9 | |
| Supraglottic larynx | 2 | |
| Glottic larynx | 1 | |
| Clinical nodal classification | ||
| cN0 | 25 | 83.3 |
| cN1 | 3 | 10.0 |
| cN2 | 2 | 6.7 |
| Neck dissection | ||
| Yes | 9 | 30.0 |
| Superselective neck dissection (1 or 2 levels) | 3 | |
| Levels II–V | 5 (1 bilateral) | |
| Levels II–IV | 1 (bilateral) | |
| No | 21 | 70.0 |
| Surgical margin status | ||
| Clear | 10 | 33.3 |
| Close (<5 mm) | 8 | 26.7 |
| Positive | 10 | 33.3 |
| Not assessable (coagulation artifacts) | 2 | 6.7 |
| Pathological tumor classification | ||
| pT0/rpT0 oropharynx | 1 | 3.3 |
| pT1/rpT1 | 18 | 60.0 |
| Oropharynx | 9 | |
| Supraglottic larynx | 5 | |
| Hypopharynx | 4 | |
| pT2/rpT2 | 7 | 23.3 |
| Oropharynx | 5 | |
| Supraglottic larynx | 1 | |
| Hypopharynx | 1 | |
| pT4/rpT4 glottic larynx | 1 | 3.3 |
| pTx/rpTx (not specified) | 3 | 10.0 |
| Pathological nodal classification | ||
| pNx | 21 | 70.0 |
| pN0 | 3 | 10.0 |
| pN1 | 3 | 10.0 |
| pN2a | 0 | |
| pN2b | 2 | 6.6 |
| pN2c | 1 | 3.3 |
| Adjuvant treatment | ||
| No adjuvant treatment, follow-up | 19 | 63.3 |
| Radiotherapy | 4 | 13.3 |
| Chemoradiotherapy | 2 | 6.7 |
| Photodynamic therapy | 2 | 6.7 |
| Surgery (TLM, total laryngectomy) | 2 | 6.7 |
| Undetermined (early death) | 1 | 3.3 |
TLM, transoral laser microsurgery.